Review anchor
Programmed cell death protein 1/Programmed cell death 1 ligand 1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Programmed cell death protein 1/Programmed cell death 1 ligand 1
CHEMBL4523993
PROTEIN COMPLEX
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Programmed cell death protein 1/Programmed cell death 1 ligand 1 as ChEMBL target CHEMBL4523993, mapped to UniProt Q15116. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4523993
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q15116
Programmed cell death protein 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Programmed cell death protein 1/Programmed cell death 1 ligand 1 matters
Programmed cell death protein 1/Programmed cell death 1 ligand 1 is reviewed as Programmed cell death protein 1 (UniProt Q15116); the current evidence base includes 2 approved drugs, 4178 compounds, and 296 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Programmed cell death protein 1
Programmed cell death protein 1 Sequence length is 288 aa.
Review this target as Programmed cell death protein 1/Programmed cell death 1 ligand 1, mapped to UniProt Q15116. ChEMBL maps the protein component as Programmed cell death protein 1. Sequence length is 288 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q15116
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 4178 compounds, and 296 assays for this target. The dominant activity type is IC50. CHEMBL5411833 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL5411833 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Programmed cell death protein 1/Programmed cell death 1 ligand 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q15116, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4178
Total Compounds
296
Total Assays
2
Approved Drugs
IC50: 5693.0, KI: 1.0, EC50: 504.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5411833
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL6041367
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL5816891
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL5182195
|
10.4 | IC50 | — |
|
|
No preferred name
CHEMBL6061706
|
10.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PYRVINIUM
CHEMBL1201303
|
1982 |
Source Header